The Polynovo Ltd (ASX: PNV) share price is currently trading 7% higher at $1.18 after levelling off of its intraday peak of $1.21.
While there’s been nothing remarkable out of Polynovo’s camp, the healthcare sector is staging a comeback rally today, showing signs of life once more.
Over the past week, Polynovo shares have surged 17% and are now up around 9% for the previous month of trade.
Why is the Polynovo share price so healthy today?
The biotech company’s shares are surging along with the broad healthcare sector today.
The S&P/ASX 200 Health Care index (XHJ) is currently up less than 1% today and around 2% over the week after sliding hard at the restart of trade in January. It is still down 10.5% despite staging a recovery these past 2 weeks.
Short interest had been high on Polynovo up until this week, with up to 9% of its float designated to short sellers on 21 March.
As a ratio, short interest peaked for the company’s shares in December last year, at a ratio of 59.8. It has since fallen to just 14.7 at the time of writing.
The ratio is an important one in understanding the amount of selling pressure on a stock by gauging how many days it takes short sellers to repurchase their shares in the market.
If the number is high, it suggests that market pundits are bearish on the stock whereas the ratio is lower when investors are more optimistic.
In fact, just this week, the ratio has crept down 9.74 points to its current level, which suggests the market is turning more bullish, Bloomberg data reports.
Analysts are bullish too. Half of those covering the share say to buy Polynovo at its current share price, whereas the other 50% say it is a hold.
Macquarie is heavily bullish and values the company at $1.60 per share, baking in large expectations around the company’s NovoSorb sales.
The consensus price target on Polynovo is at $1.58 per share, suggesting an upside potential of 34%.
Polynovo share price snapshot
In order to return to the share price’s previous highs, the company has some serious earnings growth to produce, or investors have to pile in by the boatload. The Polynovo share price has dropped 58% in the past 12 months and is down 22% this year to date.
This suggests it must return around 150% to overcome its 12-month loss and return to its previous high.
The post Polynovo (ASX:PNV) share price spikes 7% as healthcare stages comeback rally appeared first on The Motley Fool Australia.
Should you invest $1,000 in Polynovo right now?
Before you consider Polynovo, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Polynovo wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- These are the 10 most shorted ASX shares
- These were the best performing ASX 200 share last week
- The Polynovo (ASX:PNV) share price has lost 35% this year. Is now the time to buy?
- These are the 10 most shorted ASX shares
- ASX 200 (ASX:XJO) midday update: Origin’s $250m buyback, Nickel Mines smashed
Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/Qygcd6U
Leave a Reply